

LEXICON PHARMACEUTICALS, INC./DE  
Form 8-K  
May 03, 2012

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 3, 2012

Lexicon Pharmaceuticals, Inc.  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	000-30111 (Commission File Number)	76-0474169 (I.R.S. Employer Identification Number)
---	---------------------------------------	--

8800 Technology Forest Place  
The Woodlands, Texas 77381  
(Address of principal executive  
offices and Zip Code)

(281) 863-3000  
(Registrant's telephone number,  
including area code)

Check the appropriate box below if the Form 8 K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On May 3, 2012, we issued a press release to report our financial results for the quarter ended March 31, 2012. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	— Press Release of Lexicon Pharmaceuticals, Inc. dated May 3, 2012

---

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Lexicon Pharmaceuticals, Inc.

Date: May 3, 2012

By: /s/ Brian T. Crum  
Brian T. Crum  
Vice President and General Counsel

Index to Exhibits

Exhibit No.	Description
99.1	— Press Release of Lexicon Pharmaceuticals, Inc. dated May 3, 2012

bsp;

I.

Investment company equity securities \$ \$

J.

All other equity securities 1 \$19,704 \$ 283

K.

Other securities \$ \$

L.

Total assets of all series of registrant 1 \$ 19,704 \$ 283



If filing more than one

Page 51, X box: [ ]

For period ending December 31, 2015

File number 811-10585

128. [ ] Is the timely payment of principal and interest on any of the portfolio securities held by any of Registrant's series at the end of the current period insured or guaranteed by an entity other than the issuer? (Y/N)

Y/N

[If answer is N (No), go to item 131.]

129. [ ] Is the issuer of any instrument covered in item 128 delinquent or in default as to payment of principal or interest at the end of the current period? (Y/N)

Y/N

[If answer is N (No), go to item 131.]

130. [ ] In computations of NAV or offering price per unit, is any part of the value attributed to instruments identified in item 129 derived from insurance or guarantees? (Y/N)

Y/N

131. [ ] Total expenses incurred by all series of Registrant during the current reporting period (\$000's omitted)

\$ 375

132. [ ] List the 811 (Investment Company Act of 1940) registration number for all Series of Registrant that are being included in this filing:

811-	811-	811-	811-	811-
811-	811-	811-	811-	811-
811-	811-	811-	811-	811-
811-	811-	811-	811-	811-
811-	811-	811-	811-	811-
811-	811-	811-	811-	811-
811-	811-	811-	811-	811-
811-	811-	811-	811-	811-
811-	811-	811-	811-	811-
811-	811-	811-	811-	811-

FORM N-SAR MERRILL LYNCH LIFE VARIABLE ANNUITY SEPARATE ACCOUNT C

A SEPARATE ACCOUNT OF TRANSAMERICA ADVISORS LIFE INSURANCE COMPANY

FILE NO. 811-10585

This report is signed on behalf of the registrant in the City of Cedar Rapids and the State of Iowa on the 17<sup>th</sup> day of February, 2016.

TRANSAMERICA ADVISORS LIFE  
INSURANCE

COMPANY

By: /s/ John T. Mallett  
John T. Mallett, Vice President

Witness:

Alison Ryan, Vice President